SCHEMBL2424366

SCHEMBL2424366

COc1cc(C(=O)O)c(C)cc1C(N)=O

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.50
LCK P06239 1/20 0.49
FYN P06241 1/20 0.49
NNMT P40261 1/20 0.47
KDM4E B2RXH2 5/20 0.46
HPGD P15428 3/20 0.46
CA12 O43570 1/20 0.46
CA1 P00915 1/20 0.46
CA2 P00918 1/20 0.46
CA4 P22748 1/20 0.46
CA6 P23280 1/20 0.46
CA7 P43166 1/20 0.46
TPMT P51580 1/20 0.46
CA9 Q16790 1/20 0.46
CA14 Q9ULX7 1/20 0.46
MYC P01106 1/20 0.45
HTT P42858 2/20 0.42
CYP3A4 P08684 1/20 0.42
HSD17B10 Q99714 2/20 0.41
NPC1 O15118 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6069006 0.89 LCK (0.60) ALDH1A1LCKFYNKDM4EHPGD
SCHEMBL12515489 0.83 ALDH1A1 (0.55) ALDH1A1LCKFYNKDM4EHPGD
SCHEMBL1505272 0.83 LCK (0.62) ALDH1A1LCKFYNKDM4EHPGD
SCHEMBL2429973 0.81 NNMT (0.41) ALDH1A1NNMTGABRPGABRDGABRA1
SCHEMBL2139729 0.81 LCK (0.50) ALDH1A1LCKFYNKDM4EHPGD
SCHEMBL28625696 0.81 LCK (0.55) ALDH1A1LCKFYNKDM4EHPGD
SCHEMBL12444087 0.81 ALDH1A1 (0.56) ALDH1A1LCKFYNKDM4EHPGD
SCHEMBL3345488 0.81 NNMT (0.53) ALDH1A1LCKFYNNNMTKDM4E
SCHEMBL28285146 0.81 CYP3A4 (0.61) ALDH1A1LCKFYNKDM4EHPGD
SCHEMBL6811690 0.80 KDM4E (0.49) ALDH1A1LCKFYNNNMTKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8012956-B2 Tropane compounds EXELIXIS, INC. (US) 2011-09-06 US disclosed
US-8012956-B2 Tropane compounds EXELIXIS, INC. (US) 2011-09-06 US disclosed
US-8012956-B2 Tropane compounds EXELIXIS, INC. (US) 2011-09-06 US disclosed
EP-2074120-B1 TROPANE COMPOUNDS EXELIXIS INC (US) 2010-03-03 EP disclosed
EP-2074120-B1 TROPANE COMPOUNDS EXELIXIS INC (US) 2010-03-03 EP disclosed
EP-2074120-A1 TROPANE COMPOUNDS Exelixis, Inc. (US) 2009-07-01 EP disclosed
US-20090163471-A1 Tropane compounds EXELIXIS, INC. 2009-06-25 US disclosed
US-20090163471-A1 Tropane compounds EXELIXIS, INC. 2009-06-25 US disclosed
US-20090163471-A1 Tropane compounds EXELIXIS, INC. 2009-06-25 US disclosed
WO-2009055077-A1 TROPANE COMPOUNDS EXELIXIS, INC. (US) 2009-04-30 WO disclosed
WO-2009055077-A1 TROPANE COMPOUNDS EXELIXIS, INC. (US) 2009-04-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090163471-A1 Tropane compounds ADRA1B, ADRA2B, ADRB2 ALDH1A1 323/4885LCK 2211/4885FYN 2388/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.